TABRECTA is the first treatment that specifically treats people with mNSCLC who have MET exon 14 skipping.
Learn more about TABRECTA
Understanding MET Exon 14 Skipping
In Metastatic Non-Small Cell Lung Cancer
About NSCLC
Non-small cell lung cancer (NSCLC) is not just 1 disease, but many types of disease with specific genetic differences. Certain people may have noninherited gene mutations that can cause their cancer cells to grow and multiply.
About MET exon 14 skipping
MET exon 14 skipping is caused by mutations in the MET gene
-
Gene changes (mutations) have been linked to cancer growth in metastatic non-small cell lung cancer (mNSCLC)
- Certain noninherited gene mutations can cause MET exon 14 skipping, which is an abnormal change in a gene that makes a protein called mesenchymal-epithelial transition (MET)
-
MET exon 14 skipping has been linked to cancer growth in mNSCLC
-
MET exon 14 skipping can be detected by an FDA-approved comprehensive biomarker test
- For people with mNSCLC with MET exon 14 skipping, there is an option to take the first FDA-approved targeted therapy, TABRECTA
